Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS adolescent vaccination “hot buttons”

Executive Summary

The HHS National Vaccines Advisory Committee's adolescent working group identifies three "hot button" issues concerning adolescent immunization: school mandates for vaccination, informed consent and use of non-traditional venues for adolescent immunization. The group hopes to publish a draft "defining the problems" in the upcoming months and put out a report within a year. A number of adolescent vaccines have been approved recently, including Merck's human papillomavirus vaccine Gardasil and Sanofi-Pasteur's meningococcal conjugate vaccine Menactra (1"The Pink Sheet" Feb. 28, 2005, p. 28)...

You may also be interested in...



Menactra Launches For 11, 12, 15 Year Olds; First In Wave Of Teen Vaccines?

Sanofi-Pasteur will have approximately 5 mil. doses of Menactra (meningococcal quadrivalent conjugate vaccine) available for use in the U.S. during the first 12 months following launch

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel